How this CFLT vs CORZ comparison is calculated

All metrics are based on trailing twelve months (TTM) financial data, consensus analyst estimates, and standardized valuation ratios. Data is sourced from Financial Modeling Prep and SEC EDGAR. Figures are normalized to ensure a fair comparison between Confluent, Inc. and Core Scientific, Inc.. Analyst price targets and ratings are aggregated from Wall Street consensus as of 2026-05-19.

Quick verdict: Confluent, Inc. vs Core Scientific, Inc. in 2026

Confluent, Inc. emerges as the growth leader, showcasing robust revenue expansion, while Core Scientific, Inc. garners a significant valuation edge due to its less negative earnings multiple and appealing analyst sentiment. CFLT holds a superior position in terms of margin performance and free cash flow generation, contrasting with CORZ, which stands out with a more optimistic price target upside and strong analyst endorsement. Not investment advice.

Confluent, Inc. vs Core Scientific, Inc.: key metrics side by side

A full side-by-side look at Confluent, Inc. (CFLT) and Core Scientific, Inc. (CORZ) across earnings multiples, profitability, revenue momentum, and analyst sentiment — data updated 2026-05-19.

Relative valuation: CFLT vs CORZ

A direct valuation comparison between Confluent, Inc. and Core Scientific, Inc. reveals a complex landscape, particularly given both companies report negative earnings. CFLT, with a price-to-earnings multiple of -36.93x, is designated as having an edge by our scorecard, implying its losses are relatively smaller compared to its stock price when juxtaposed with CORZ. Core Scientific, Inc. currently trades at an earnings multiple of -6.26x, which appears less negative in absolute terms but suggests a higher loss per share relative to its valuation. This fundamental divergence in their P/E ratios indicates different market perceptions of their underlying profitability challenges and future prospects.

Moving beyond earnings multiples, Core Scientific, Inc. presents a strikingly negative price-to-book ratio of -5.83x, a stark contrast to Confluent, Inc.’s positive P/B of 9.33x. This negative book value for CORZ can be indicative of significant accumulated losses eroding shareholder equity, making its stock appear ‘cheaper’ in a highly unconventional sense. However, when examining the discounted cash flow (DCF) models, CFLT’s implied upside sits at a notable -63.7%, suggesting considerable overvaluation by this metric. Core Scientific, Inc., on the other hand, faces an even more pronounced challenge, with its DCF pointing to a substantial -120.0% downside. Based on current consensus data, this suggests that while CORZ’s multiples might seem lower in some regards, its underlying intrinsic value, as per the DCF model, is significantly more distressed. Investors assessing relative valuation must weigh the less negative P/E of CFLT against the deeply negative book value and DCF of CORZ, acknowledging the significant inherent risks in both.

Revenue momentum: Confluent, Inc. vs Core Scientific, Inc.

Confluent, Inc. demonstrates a robust top-line expansion, reporting a year-over-year revenue growth rate of 21.1%. This momentum reflects strong market demand for its data streaming platform and services, positioning CFLT as a clear leader in revenue generation compared to its peer. The company’s ability to consistently grow its sales base indicates healthy adoption and an expanding customer footprint, vital for long-term viability in the competitive technology sector. This consistent progression suggests a positive growth trajectory for Confluent, Inc. in the near to medium term.

In stark contrast, Core Scientific, Inc. faced a significant contraction in its topline, with revenue growth plummeting by -37.5%. This considerable decline indicates substantial operational headwinds, possibly influenced by fluctuations in cryptocurrency markets or increased competition within the digital asset mining space. Despite this revenue challenge, CORZ manages a positive EBITDA margin of 25.09%, which is a notable achievement when compared to CFLT’s EBITDA margin of -26.79%. While Confluent, Inc. prioritizes market share and growth, potentially at the expense of current operational profitability, Core Scientific, Inc. shows a capacity for generating positive earnings before interest, taxes, depreciation, and amortization, albeit on a shrinking revenue base. This gap in revenue expansion may not persist if market conditions for CORZ’s primary business improve, but currently, CFLT exhibits a much stronger growth trajectory on the sales front.

Profitability and cash generation: CFLT vs CORZ

When analyzing profitability, Confluent, Inc. (CFLT) exhibits a net margin of -25.31%, which, while negative, represents a significantly more favorable position than Core Scientific, Inc.’s staggering net margin of -342.93%. This substantial difference underscores the severe unprofitability currently faced by CORZ, indicating that its costs far outweigh its revenues to an extreme degree. For CFLT, the negative net margin suggests ongoing investments into growth or operational inefficiencies, but at a much more manageable level. Neither company currently offers a positive return on equity (ROE), with both reporting N/A%, indicating either negative equity or reporting practices that make ROE calculation non-standardized.

Regarding cash conversion, Confluent, Inc. generates a modest positive free cash flow (FCF) yield of 0.46%. This positive FCF yield for CFLT indicates that the company, despite its negative net income, is able to generate some cash from its operations, which is a crucial sign of financial health and sustainability. Conversely, Core Scientific, Inc. struggles with a deeply negative FCF yield of -6.29%, highlighting its inability to generate sufficient cash to cover its operating and capital expenditures. This negative free cash flow yield for CORZ points to an ongoing reliance on external financing or asset sales to sustain operations. Therefore, in terms of generating cash relative to its price, Confluent, Inc. demonstrates a considerably stronger position and greater financial resilience.

Wall Street view: Confluent, Inc. vs Core Scientific, Inc. analyst ratings

The consensus on Wall Street presents a mixed picture for Confluent, Inc. (CFLT). Out of 38 analysts covering the stock, 47.4% currently recommend a “Buy” rating, leading to an overall “Hold” consensus. The average analyst target price for CFLT stands at $30.85, suggesting a slight downside of -0.5% from its current trading price. This indicates that while a significant portion of analysts see potential, the broader sentiment is cautious, possibly reflecting current valuation concerns or expected stabilization in growth.

Core Scientific, Inc. (CORZ), on the other hand, garners a far more optimistic outlook from the analyst community. A robust 86.4% of the 22 analysts following CORZ recommend a “Buy” rating, resulting in a firm “Buy” consensus for the stock. Their collective price target is set at $31.6, implying a substantial upside of +34.1% from its current price. This strong endorsement and significant potential upside suggest that analysts are bullish on Core Scientific, Inc.’s future prospects, perhaps anticipating a turnaround in its operational performance or a favorable shift in market conditions. It’s important to remember that these price targets may vary depending on future estimate revisions and market dynamics.

Which investor profile fits CFLT vs CORZ?

For a growth-oriented investor, Confluent, Inc. (CFLT) appears to be the more suitable candidate. With a strong year-over-year revenue growth of 21.1%, CFLT demonstrates a clear ability to expand its market presence and top-line figures. Its focus on developing and delivering a cutting-edge data streaming platform aligns well with investors seeking companies poised for significant expansion, even if it entails sacrificing immediate profitability. Core Scientific, Inc., with its negative revenue growth of -37.5%, does not currently exhibit the characteristics typically sought by pure growth investors.

Value investors face a challenging decision given the negative profitability metrics for both companies. However, for those willing to consider high-risk, deeply undervalued (by some measures) opportunities, Core Scientific, Inc. (CORZ) might present a peculiar case. While its P/E ratio is -6.26x (less negative than CFLT’s -36.93x), and it has a negative price-to-book ratio of -5.83x, these metrics suggest the market has significantly discounted the stock due to its severe unprofitability and negative equity. Confluent, Inc., despite its more negative P/E, has a less drastically negative DCF upside (-63.7% compared to CORZ’s -120.0%), implying a slightly less severe overvaluation by that specific model. The value proposition here is highly speculative and requires a deep understanding of each company’s path to profitability.

For income investors, neither Confluent, Inc. nor Core Scientific, Inc. is a suitable option. Both companies currently offer a 0% dividend yield, indicating that they prioritize reinvesting earnings back into the business rather than returning capital to shareholders through dividends. This is typical for growth-focused technology companies or those in a turnaround phase. Therefore, investors seeking regular income streams would need to look elsewhere. This is not investment advice. Always do your own research.

More Confluent, Inc. and Core Scientific, Inc. comparisons

Confluent, Inc. (CFLT) full stock analysis · Core Scientific, Inc. (CORZ) full stock analysis · All stock comparisons